[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Celcuity Inc (CELC)

Celcuity Inc (CELC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,290,920
  • Shares Outstanding, K 48,766
  • Annual Sales, $ 0 K
  • Annual Income, $ -177,040 K
  • EBIT $ -187 M
  • EBITDA $ -183 M
  • 60-Month Beta 0.16
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 79.81

Options Overview Details

View History
  • Implied Volatility 81.64% (+0.50%)
  • Historical Volatility 78.21%
  • IV Percentile 84%
  • IV Rank 11.48%
  • IV High 317.42% on 07/25/25
  • IV Low 51.06% on 08/19/25
  • Expected Move (DTE 31) 14.05 (15.65%)
  • Put/Call Vol Ratio 0.28
  • Today's Volume 181
  • Volume Avg (30-Day) 2,528
  • Put/Call OI Ratio 0.99
  • Today's Open Interest 25,767
  • Open Int (30-Day) 29,138
  • Expected Range 75.73 to 103.83

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.08
  • Number of Estimates 2
  • High Estimate $-1.04
  • Low Estimate $-1.12
  • Prior Year $-1.04
  • Growth Rate Est. (year over year) -3.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
84.99 +6.58%
on 07/16/26
117.21 -22.72%
on 07/07/26
+2.81 (+3.21%)
since 06/18/26
3-Month
82.55 +9.72%
on 06/18/26
151.02 -40.02%
on 05/04/26
-35.50 (-28.15%)
since 04/21/26
52-Week
13.50 +570.93%
on 07/22/25
151.02 -40.02%
on 05/04/26
+77.03 (+568.94%)
since 07/21/25

Most Recent Stories

More News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC

NEW YORK , July 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Celcuity Inc. ("Celcuity" or the "Company") (NASDAQ: CELC).  Such investors are advised to...

CELC : 90.25 (+2.57%)
Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer

REVTORPYK  is the first and only FDA-approved therapy that inhibits all class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2 In the Phase 3 VIKTORIA-1 trial, REVTORPYK combined...

CELC : 90.25 (+2.57%)
Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032

MINNEAPOLIS, June 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) (“Celcuity” or the “Company”), a clinical-stage biotechnology company focused on the development of targeted therapies...

CELC : 90.25 (+2.57%)
Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032

MINNEAPOLIS, June 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) (“Celcuity” or the “Company”), a clinical-stage biotechnology company focused on the development of targeted therapies...

CELC : 90.25 (+2.57%)
Celcuity’s Gedatolisib Combination Regimens Doubled the Likelihood of Survival without Disease Progression or Death Compared to Alpelisib plus Fulvestrant in the PIK3CA Mutant Cohort of the Pivotal Phase 3 VIKTORIA-1 Trial in Patients with...

Gedatolisib plus fulvestrant and palbociclib (the “gedatolisib-triplet”) reduced the risk of disease progression or death by 50% vs. alpelisib plus fulvestrant (HR=0.50; 95% CI: 0.37–0.68; p

CELC : 90.25 (+2.57%)
Celcuity to Hold Conference Call to Discuss Results for the PIK3CA Mutant Cohort of the Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib Regimens in HR+/HER- Advanced Breast Cancer on June 2, 2026

MINNEAPOLIS, June 01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid...

CELC : 90.25 (+2.57%)
Celcuity To Participate in Upcoming Investor Conferences

MINNEAPOLIS, May 28, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid...

CELC : 90.25 (+2.57%)
Celcuity Q1 Earnings Call Highlights

Celcuity (NASDAQ:CELC) reported a wider first-quarter loss as the biotechnology company increased spending tied to commercial launch preparations and continued development of gedatolisib, its investigational...

CELC : 90.25 (+2.57%)
Celcuity Inc. Reports Release of First Quarter 2026 Financial Results and Provides Corporate Update

  Phase 3 VIKTORIA-1 trial achieved primary endpoint with clinically meaningful improvement in progression-free survival in PIK3CA mutant cohort; detailed data for gedatolisib regimens will be presented...

CELC : 90.25 (+2.57%)
Celcuity’s Phase 3 VIKTORIA-2 Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive Patients

MINNEAPOLIS, May 14, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid...

CELC : 90.25 (+2.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Celcuity Inc. is a cellular analysis company. It engaged in discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. The company's proprietary CELx diagnostic platform uses a patient's...

See More

Key Turning Points

3rd Resistance Point 95.01
2nd Resistance Point 93.55
1st Resistance Point 90.77
Last Price 90.25
1st Support Level 86.54
2nd Support Level 85.08
3rd Support Level 82.30

See More

52-Week High 151.02
Fibonacci 61.8% 98.49
Last Price 90.25
Fibonacci 50% 82.26
Fibonacci 38.2% 66.03
52-Week Low 13.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.